Posaconazole reduces infection in AML patients
The incidence of pneumonia and invasive pulmonary aspergillosis in acute myeloid leukemia patients was reduced when they were given posaconazole (Noxafil) as prophylaxis.
The incidence of pneumonia and invasive pulmonary aspergillosis in acute myeloid leukemia patients was reduced when they were given posaconazole (Noxafil) as prophylaxis.
According to a study presented at the 2009 Interscience Conference on Antimicrobial Agents and Chemotherapy in San Francisco, the number of febrile days, incidence rates of invasive fungal diseases and aspergillosis, and duration of hospitalization decreased significantly (abstract 1052).
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
